R. Mcelhinney

发表

Influence of O6-benzylguanine on the anti-tumour activity and normal tissue toxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea and molecular combinations of 5-fluorouracil and 2-chloroethyl-1-nitrosourea in mice

M. Bibby, G. Margison, J. Rafferty, 1999, British Journal of Cancer.

Intermediates in the Ing-Manske reaction

R. Mcelhinney, O. M. S. Curley, J. Mccormick, 2003 .

O6-alkylguanine-DNA alkyltransferase inactivation in cancer chemotherapy.

G. Margison, R. Mcelhinney, T. Mcmurry, 2003, Mini reviews in medicinal chemistry.

O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts

A. Howell, M. Clemons, G. Margison, 2005, British Journal of Cancer.

Syntheses of 2-amino-4,6-dichloro-5-nitropyrimidine and 2-amino-4,5,6-trichloropyrimidine: an unusual aromatic substitution

T. McCabe, I. Rozas, T. Mcmurry, 2009 .

Synthesis of Potential Anticancer Agents. V. Azetidines1,2

W. R. Vaughan, R. Mcelhinney, B. B. Millward, 1961 .

Nitrosoureas from chemist to physician: classification and recent approaches to drug design.

R. Mcelhinney, J. McCormick, 1990, European journal of cancer.

Novel synthesis of O6-alkylguanine containing oligodeoxyribonucleotides as substrates for the human DNA repair protein, O6-methylguanine DNA methyltransferase (MGMT)

G. Margison, Nicola Glynn, David M Williams, 2006, Nucleic acids research.

O6‐(4‐bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts

G. Margison, N. Thatcher, M. Middleton, 2000, International journal of cancer.

Inactivation of O6-alkylguanine-DNA alkyltransferase. 1. Novel O6-(hetarylmethyl)guanines having basic rings in the side chain.

A. Watson, M. Middleton, G. Margison, 1998, Journal of medicinal chemistry.

Dual repair modulation reverses Temozolomide resistance in vitro.

M. Ranson, G. Margison, T. McMurry, 2004, Molecular cancer therapeutics.

Effect of O6‐(4‐bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model

G. Margison, N. Thatcher, M. Middleton, 2002, International journal of cancer.

Nucleoside analogues. Part 10. Synthesis of three unusual 5-fluorouracil seco-nucleosides incorporating N-(2-chloroethyl)-N-nitrosourea residues

R. Mcelhinney, J. McCormick, N. M. Lucey, 1990 .

Nucleoside analogues. 9. Seco-nucleoside analogues of some 5-fluorouracil/nitrosourea molecular combinations having uracil as base: synthesis and anti-tumour activity.

J. Double, M. Bibby, P. Dumont, 1989, Anti-cancer drug design.

Nucleoside analogues. 13. The effect on anti-tumour activity of varying the uracil 5-substituent and the point of attachment (N1 or N3) of the uracil moiety in seco-nucleoside nitrosoureas.

J. Double, M. Bibby, P. Dumont, 1993, Anti-cancer drug design.

Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase.

M. Ranson, G. Margison, P. Lorigan, 2004, Molecular cancer therapeutics.

Lomeguatrib, a Potent Inhibitor of O6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors

M. Ranson, G. Margison, J. Bridgewater, 2006, Clinical Cancer Research.

Professional Identity Development: A Grounded Theory Study of Clinical Psychology Trainees

R. Mcelhinney, 2008 .

The Angas Zn-Pb-Ag deposit in the Kanmantoo Group, South Australia: Synsedimentary or metamorphic?

R. Mcelhinney, R. Both, S. Toteff, 1995 .

Antitumor effects of bis-thiosemicarbazones--inhibition of deoxyribonucleic acid synthesis in vitro.

D. Kessel, R. Mcelhinney, 1975, Biochemical pharmacology.

Anticancer agents. IV. The antitumor activity of some 1,4- and 1,5-(bisthiosemicarbazones) and of related heterocycles.

M. McInerney, V. Barry, M. Conalty, 1970, Journal of Medicinal Chemistry.

Towards more specific O6-methylguanine-DNA methyltransferase (MGMT) inactivators.

G. Margison, I. Rozas, T. McMurry, 2011, Bioorganic & medicinal chemistry.

Evolution of molecular combinations involving 5-fluorouracil.

R. Mcelhinney, C. Lucey, J. McCormick, 1988, Cancer treatment reviews.

Nucleoside analogues. Part 12. The anomalous 19F NMR spectrum of B.3996, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea and synthesis of its N′-nitroso isomer and related compounds

R. Maxwell, R. Mcelhinney, T. Mcmurry, 1991 .

Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model

M. Bibby, P. Loadman, J. Double, 1992, Investigational New Drugs.

Nucleoside analogues: 8. Some isomers of B.3839, the original 5-fluorouracil/nitrosourea molecular combination, and their effect on colon, breast and lung tumours in mice.

J. Double, M. Bibby, P. Dumont, 1989, Anti-Cancer Drug Design.

Nucleoside analogues: 7. Effect on colon, breast and lung tumours in mice of 5-fluorouracil/nitrosourea molecular combinations incorporating alkoxy and oxidized sulphur functions.

J. Double, M. Bibby, P. Dumont, 1989, Anti-Cancer Drug Design.

Nucleoside analogues. Part 2. Further molecular combinations of (5-substituted) uracil and N-(2-chloroethyl)-N-nitrosourea residues as anticancer agents

R. Mcelhinney, J. McCormick, 1985 .

QSAR and Chemical Read-Across Analysis of 370 Potential MGMT Inactivators to Identify the Structural Features Influencing Inactivation Potency

G. Margison, R. Zhong, Lijiao Zhao, 2023, Pharmaceutics.

An evaluation of a group-based cognitive behavioural therapy intervention for low self-esteem

J. Kerr, R. Mcelhinney, S. Swartzman, 2021, Behavioural and Cognitive Psychotherapy.